Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- AstraZeneca to Recommend 5 mg Starting Dose of Crestor to Asians: EU Label
May 16, 2005
- Mediceo HD to Merge with Paltac
May 9, 2005
- DPC Hospitals Conducting More Advanced Medical Procedures
May 9, 2005
- Huntingdon Life Sciences to Strengthen Business with Japanese Clients
May 9, 2005
- Just 10.9% of Hospitals Have Switched to Generics Since Introduction of DPC
May 9, 2005
- MEDICAL DEVICE NEWS IN BRIEF
May 9, 2005
- Chuikyo Starts Studies on Med Services Provided Beyond Designated Number of Times
May 9, 2005
- DPC Increased Use of Generics in 55.6% of Hospital: Prof. Kawabuchi
May 9, 2005
- NHI Pricing Rule Needs Radical Revisions: Chuikyo
May 9, 2005
- 41.2% of Suspected COPD Patients Do Not Intend to Consult a Physician
May 9, 2005
- CPhI Japan/ICSE Japan 2005
May 9, 2005
- Draft GL on Management of Pancreatic Cancer Published: JSGE
May 9, 2005
- BUSINESS NEWS IN BRIEF
May 9, 2005
- R&D NEWS IN BRIEF
May 9, 2005
- JPMA to Introduce "Good Communication 2005" Campaign
May 9, 2005
- Chugai, 2 Partners Establish Drug Discovery Research Institute
May 9, 2005
- BULLETIN
May 9, 2005
- Maximize Product Value as Competition Heats Up: Mr Suganuma
May 9, 2005
- KSK Will Not Join the Kyoso Mirai Group: Mr Fukada
May 9, 2005
- Mochida Aiming for Sales of \76 Bil. in FY2007
May 9, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…